GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sunder Biomedical Tech Co Ltd (ROCO:4115) » Definitions » EBIT

Sunder Biomedical Tech Co (ROCO:4115) EBIT : NT$33.3 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Sunder Biomedical Tech Co EBIT?

Sunder Biomedical Tech Co's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was NT$27.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was NT$33.3 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sunder Biomedical Tech Co's annualized ROC % for the quarter that ended in Jun. 2024 was 2.65%. Sunder Biomedical Tech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 5.46%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sunder Biomedical Tech Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was 3.78%.


Sunder Biomedical Tech Co EBIT Historical Data

The historical data trend for Sunder Biomedical Tech Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunder Biomedical Tech Co EBIT Chart

Sunder Biomedical Tech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial 28.09 68.97 96.96 22.99 -28.01

Sunder Biomedical Tech Co Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.34 -11.35 -33.89 5.88 27.41

Competitive Comparison of Sunder Biomedical Tech Co's EBIT

For the Medical Instruments & Supplies subindustry, Sunder Biomedical Tech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunder Biomedical Tech Co's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sunder Biomedical Tech Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sunder Biomedical Tech Co's EV-to-EBIT falls into.


;
;

Sunder Biomedical Tech Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$33.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunder Biomedical Tech Co  (ROCO:4115) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sunder Biomedical Tech Co's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

ROC % (Q: Jun. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Jun. 2024 ))/ count )
=31.848 * ( 1 - 9.92% )/( (1123.393 + 1043.926)/ 2 )
=28.6886784/1083.6595
=2.65 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1405.285 - 118.071 - ( 163.821 - max(0, 430.674 - 658.513+163.821))
=1123.393

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1279.708 - 102.233 - ( 133.549 - max(0, 310.041 - 521.81+133.549))
=1043.926

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sunder Biomedical Tech Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Jun. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=54.814/( ( (696.034 + max(323.554, 0)) + (706.956 + max(281.174, 0)) )/ 2 )
=54.814/( ( 1019.588 + 988.13 )/ 2 )
=54.814/1003.859
=5.46 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(244.656 + 134.873 + 111.757) - (118.071 + 0 + 49.661)
=323.554

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(261.341 + 118.721 + 4.3169999999999) - (102.233 + 0 + 0.97199999999998)
=281.174

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sunder Biomedical Tech Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2024 )
=33.285/881.176
=3.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunder Biomedical Tech Co EBIT Related Terms

Thank you for viewing the detailed overview of Sunder Biomedical Tech Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunder Biomedical Tech Co Business Description

Traded in Other Exchanges
N/A
Address
No. 1-67, Zhongzheng Road, Chung-Ming Village, Pao-Chung Hsiang, Yunlin, TWN, 63441
Sunder Biomedical Tech Co Ltd is engaged in providing medical devices. Its products include Protective Goggles; Meltblown Nonwoven Fabric/Mask; Suction Irrigation Set; Smoke Filter; Endo Bag; Blood Line Set for Hemodialysis and others.

Sunder Biomedical Tech Co Headlines

No Headlines